Provided by Tiger Trade Technology Pte. Ltd.

Argenx SE

1,031.66
+8.450.83%
Post-market: 1,031.660.00000.00%16:15 EDT
Volume:227.99K
Turnover:233.74M
Market Cap:64.52B
PE:39.36
High:1,039.36
Open:1,010.78
Low:1,005.78
Close:1,023.21
52wk High:1,061.57
52wk Low:661.85
Shares:62.54M
Float Shares:62.45M
Volume Ratio:0.86
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):26.21
EPS(LYR):19.57
ROE:23.63%
ROA:11.63%
PB:7.67
PE(LYR):52.72

Loading ...

ADRs Close Higher; Argenx SE Climbs 16%

Dow Jones
·
Aug 18

William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path

TIPRANKS
·
Aug 18

Argenx Stock Heads for Record After Blockbuster Drug Delivers Another Win

Dow Jones
·
Aug 18

argenx SE Stock (ARGX) Moved Up by 16.67% on Aug 17: Drivers Behind the Movement

TradingKey
·
Aug 18

Argenx Price Target Raised to $1215.00/Share from $1075.00 by Piper Sandler

Dow Jones
·
Aug 18

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

MT Newswires Live
·
Aug 17

Wedbush Adjusts Argenx PT to $1,150 From $1,050, Maintains Outperform Rating

MT Newswires Live
·
Aug 17

Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results

TIPRANKS
·
Aug 17

Argenx SE up over 15%, on Pace for Largest Percent Increase Since July 2023

Dow Jones
·
Aug 17

Argenx rises 14.9%

TIPRANKS
·
Aug 17

Movement Alert|Argenx SE Rises 9.45% in Regular Trading, Phase 3 Trial of Efgartigimod in Autoimmune Myositis Meets Primary Endpoint

Market Focus
·
Aug 17

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Lower Rate Hike Expectations

MT Newswires Live
·
Aug 17

Sector Update: Healthcare

MT Newswires Live
·
Aug 17

Argenx price target raised to $1,215 from $1,075 at Piper Sandler

TIPRANKS
·
Aug 17

Movement Alert|Argenx SE Rises 5% in Pre-Market Trading, Phase 3 Trial of Efgartigimod in Autoimmune Myositis Meets Primary Endpoint

Market Focus
·
Aug 17

argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study

MT Newswires Live
·
Aug 17

Argenx Shares Rise After Positive Results from Phase 3 Study of Efgartigimod

Dow Jones
·
Aug 17

European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading

MT Newswires Live
·
Aug 14

Argenx Advances Empasiprubart in Rare Nerve Disorder, Adding Long-Term Upside for ARGX Investors

TIPRANKS
·
Aug 14

Argenx resumed with a Buy at Guggenheim

TIPRANKS
·
Aug 05